Brain Safe: Consumer Intervention to Reduce Exposure to Drugs Linked to Alzheimer's Disease

단계 해당 없음 완료 NCT04121858

대상 질환	Alzheimer Disease, Dementia
임상 단계	단계 해당 없음
스폰서	Indiana University
상태	완료
참여자 수	706 명
중재(약물)	Brain Safe App, Attention Control App
시작일	2019년 10월 16일
완료일	2025년 2월 27일
결과 공개일	2026년 7월 20일

요약

This study is an RCT to evaluate the effectiveness of Brain Safe on reducing anticholinergic exposure. Over 42 months, the trial will enroll 700 community-dwelling older adults who were prescribed one or more strong anticholinergics. Participants will be randomized to use the Brain Safe app or an attention control medication list app for 12 months, with monthly usage reminders.

Total Standardized Daily Dose (TSDD) - From Medical Records

Baseline, 6 months, 12 Months · Standardized Doses Per Day

Brain Safe App	1.59 ± 3.04 Standardized Doses Per Day
Attention Control App	1.68 ± 3.57 Standardized Doses Per Day
Brain Safe App	0.86 ± 1.61 Standardized Doses Per Day
Attention Control App	1.19 ± 3.53 Standardized Doses Per Day
Brain Safe App	1.27 ± 2.51 Standardized Doses Per Day
Attention Control App	1.29 ± 3.18 Standardized Doses Per Day

Log Transformed Total Standardized Daily Dose (TSDD) - From Medical Records

Baseline, 6, and 12 Months · ln(doses per day)

Brain Safe App	-0.93 ± 2.45 ln(doses per day)
Attention Control App	-1.12 ± 2.70 ln(doses per day)
Brain Safe App	-3.32 ± 3.50 ln(doses per day)
Attention Control App	-3.01 ± 3.52 ln(doses per day)
Brain Safe App	-3.04 ± 3.68 ln(doses per day)
Attention Control App	-2.69 ± 3.59 ln(doses per day)

p-value	0.0156
Esttimated marginal means (EMMs)	-0.61 (95% CI -1.10–-0.12)

BENITIONS에서 보기 ClinicalTrials.gov 원문 보기

같은 질환의 다른 임상

Brain Energy for Amyloid Transformation in Alzheimer's Disease Study — Wake Forest University Health Sciences
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss — Eli Lilly and Company
Using a Wireless Controller to Deliver a Lighting Intervention to Persons With Dementia — Icahn School of Medicine at Mount Sinai
Deprescribing in Patients Living With Dementia With Caregiver and Provider Nudges — Brigham and Women's Hospital
Technology and Family Thriving Study — University of California, Santa Barbara
Community-based Brain Health Program to Address Dementia Risk — Posit Science Corporation

전체 임상

이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.

English 한국어 日本語中文 Русский